Aubex Therapeutics

Executive Summary

Aubex Therapeutics is a private, preclinical-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is dedicated to discovering and developing novel small molecule therapies for oncology, aiming to advance cancer treatment through innovative discovery approaches. With a focus on addressing unmet medical needs in oncology, Aubex leverages its proprietary platform to identify and optimize small molecule candidates targeting key cancer pathways. As a preclinical entity, the company has not yet disclosed specific pipeline details or financials, but its efforts are centered on advancing lead programs toward investigational new drug (IND)-enabling studies and eventual clinical trials. The biotech operates in a competitive landscape, yet its commitment to innovation positions it as a potential player in the oncology space, pending successful execution of its development milestones.

Upcoming Catalysts (preview)

• TBDLead Program IND Filing25% success
• Q4 2026Series A Financing Announcement40% success
• Q3 2026P Research/Preclinical Data Presentation at a Major Conference30% success